Allarity Therapeutics Inc... (ALLR)
undefined
undefined%
At close: undefined
1.02
-0.49%
After-hours Dec 13, 2024, 07:56 PM EST

Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.

The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Allarity Therapeutics Inc.
Allarity Therapeutics Inc. logo
Country United States
IPO Date Dec 21, 2021
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Thomas H. Jensen

Contact Details

Address:
210 Broadway
Cambridge, Massachusetts
United States
Website https://www.allarity.com

Stock Details

Ticker Symbol ALLR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860657
CUSIP Number 016744104
ISIN Number US0167443029
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Thomas H. Jensen Founder, Chief Executive Officer & Director
Alexander Epshinsky Chief Financial Officer
Dr. Jeremy R. Graff Ph.D. President & Chief Development Officer
Dr. Jose L. Iglesias M.D. Consultant Chief Medical Officer
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer
Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder

Latest SEC Filings

Date Type Title
Nov 19, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 23, 2024 8-K Current Report
Oct 11, 2024 8-K Current Report
Oct 04, 2024 8-K Current Report
Oct 01, 2024 4 Filing
Oct 01, 2024 3 Filing
Sep 18, 2024 3 Filing